This is the outside view of a growth engine I have never seen the inside of. I wrote it against the job description for the Chief Growth Officer role, with no access to your CAC, your margin or your cohorts. So rather than assert numbers, I built the panel I would run in week one and left every assumption editable. Move the sliders. If my ranges are wrong, that is the most useful thing you could tell me.
The five readingswhat I would measure first
A four-figure order value in preventive health behaves nothing like retail. Purchase is considered, infrequent and trust-gated, so the engine lives or dies on two numbers: contribution per first order, and whether a second one ever happens. Everything else is downstream.
Contribution per first orderOrder value after clinical delivery cost, not gross revenue. This sets the ceiling on everything you can spend to acquire.
Not yet measured
Repeat within 12 monthsIn preventive health this is a re-test calendar, not a newsletter. If it is under 20%, you are running a lead-generation business, not a lifecycle one.
Not yet measured
Blended CAC vs ceilingNot channel CAC. Blended, including the organic and referral volume paid activity is quietly taking credit for.
Not yet measured
Booking-to-visit conversionThe step that hides the real leak. Interest is cheap, a booked and attended appointment is the product.
Not yet measured
Paid dependencyShare of new customers that stops arriving the day you pause spend. High dependency is not a marketing problem, it is a valuation problem.
Directional data likely exists
Four of five unmeasured is the normal state before a growth function exists. It is also the fastest thing to fix, and it costs nothing but three weeks of discipline.
Run the numbers yourselflive
The arithmetic that decides whether a four-figure-AOV health business can buy growth profitably. Defaults below are my guesses. Replace them with yours.
12-month value : CAC
2.8×
CAC ceiling at 3×
CHF 351
The most you can pay for a customer and still clear a 3× return inside twelve months.
Payback
First order
Deliberately simple. It ignores discount rate, refunds and channel mix, because the point of a day-one model is to make the constraint visible to a whole leadership team in ten seconds, not to be right to two decimals.
The protocolday 1 to day 90
Sequence matters more than content here. Most growth hires spend month one buying traffic and month six discovering the funnel leaked. I would do it the other way round.
01Day 1–30
Measure what is actually true
Rebuild tracking as one source of truth: GA4 and GTM, server-side, with health data kept out of ad platforms. Consent gaps distort channel CAC badly enough to invert a spend decision.
Cohort every customer of the last twelve months: acquisition channel, contribution after delivery cost, repeat at 3, 6 and 12 months.
Fifteen customer conversations: five who bought fast, five who bought slowly, five who never came back. One question underneath all of them, what made this urgent enough to pay for.
Publish the panel and start a weekly growth review that the founders, clinical and product all sit in.
Not doing in month one: raising spend, hiring, rebranding, or promising a number I cannot yet defend.
02Day 31–60
Fix the path before buying more traffic
Tear the funnel down step by step: ad, landing, booking, attended visit, results, next action. Fix the two worst drop-offs before touching budget.
My prior, from selling considered purchases to people entirely free to say no: the leak sits between interest and booking, and it is priced in trust, waiting time and unclear cost, not in creative.
Test structure, not tactics: two offers, three landing narratives, one pricing presentation including payment plans and any employer or insurer route.
Build the lifecycle that fits this category: pre-visit preparation, results day, a 30-day action plan, and a re-test reminder timed to the biology rather than the quarter.
Gate to phase 3: two channels holding under the CAC ceiling for two consecutive weeks.
03Day 61–90
Scale what pays, open Germany narrow
Spend rises only where 30-day CAC stays under ceiling. No channel gets budget on a promise.
Germany as a controlled test, not a launch: one city, one clinical partner, one channel, one offer, German-language proof and claims wording reviewed against HWG before a single euro goes live.
Open the CAC-free lever in parallel: employers and insurers. I built a B2B function from zero to CHF 1M+ in under two years at Decathlon Switzerland, and in this category it is the cheapest volume in the building.
Hire in this order and not before the panel exists: performance marketer, lifecycle owner, analyst.
Kill criterion: German CAC above 130% of Swiss CAC at week eight and no clear path down, stop and re-enter later.
Why Germany is not Switzerlandmarket entry
The most common way a Swiss DTC health brand loses money in Germany is assuming the Swiss playbook translates. It does not, on four axes.
Axis
What changes
What I would do about it
Claims
Advertising for health services is tightly constrained. Wording that passes in CH can be actionable in DE.
Legal review of every claim before launch, one approved message library, no channel-level improvisation.
Willingness to pay
Statutory cover shapes the reference price. A self-paid four-figure panel competes with the expectation that health is already paid for.
Lead with what statutory cover does not include. Test payment plans early, not as a rescue.
Demand shape
Category search demand is thinner than brand demand suggests. Paid search will look cheap and convert poorly.
Weight toward demand creation and partnerships, hold search for branded and high-intent only.
Trust
Clinical credibility is local. A Swiss brand name carries quality signal but no medical standing.
Named local clinical partner and German medical review visible on the landing page from day one.
Four things I would want correctedwhere I am guessing
Is the second purchase a re-test, a subscription, or does it not really exist yet? The answer changes whether this is a lifecycle build or an acquisition build, and they need different first hires.
What is contribution margin after clinical delivery, honestly? Every number above hangs off it, and it is the one thing an outsider cannot estimate.
How much of current revenue comes through employers or insurers, and is that a channel or an accident?
Is Germany a partner model or your own clinical footprint? One is a marketing problem, the other is an operations problem wearing a marketing budget.